Inhibition of cancer-associated mutant isocitrate dehydrogenases: Synthesis, structure-activity relationship, and selective antitumor activity

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8307-8318

  Liu, Zhen ^a   Yao, Yuan ^a   Kogiso, Mari ^a   Zheng, Baisong ^a   Deng, Lisheng ^a   Qiu, Jihui J ^a   Dong, Shuo ^a   Lv, Hua ^b   Gallo, James M ^b   Li, Xiao Nan ^a   Song, Yongcheng ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXYPYRIDIN 2 ONE; 2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE; OXIDOREDUCTASE INHIBITOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; ALPHA-HYDROXYGLUTARATE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; PYRIDONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER INHIBITION; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; GENE MUTATION; GLIOMA CELL; MOLECULAR DOCKING; MUTANT; STRUCTURE ACTIVITY RELATION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; GLIOMA; HUMAN; METABOLISM; MOUSE; PATHOLOGY; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MICE; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908388856     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500660f     Document Type: Article

References (41)

1. Xu, X.; Zhao, J.; Xu, Z.; Peng, B.; Huang, Q.; Arnold, E.; Ding, J. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity J. Biol. Chem. 2004, 279, 33946-33957
2. Haselbeck, R. J.; McAlister-Henn, L. Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases J. Biol. Chem. 1993, 268, 12116-12122
3. Jennings, G. T.; Sechi, S.; Stevenson, P. M.; Tuckey, R. C.; Parmelee, D.; McAlister-Henn, L. Cytosolic NADP(+)-dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA J. Biol. Chem. 1994, 2689, 23128-23134
4. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A., Jr.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme Science 2008, 321, 1807-1812
5. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S. H.; Ito, S.; Yang, C.; Xiao, M. T.; Liu, L. X.; Jiang, W. Q.; Liu, J.; Zhang, J. Y.; Wang, B.; Frye, S.; Zhang, Y.; Xu, Y. H.; Lei, Q. Y.; Guan, K. L.; Zhao, S. M.; Xiong, Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases Cancer Cell 2011, 19, 17-30
6. Gross, S.; Cairns, R. A.; Minden, M. D.; Driggers, E. M.; Bittinger, M. A.; Jang, H. G.; Sasaki, M.; Jin, S.; Schenkein, D. P.; Su, S. M.; Dang, L.; Fantin, V. R.; Mak, T. W. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations J. Exp. Med. 2010, 207, 339-344
7. Yan, H.; Parsons, D. W.; Jin, G.; McLendon, R.; Rasheed, B. A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G. J.; Friedman, H.; Friedman, A.; Reardon, D.; Herndon, J.; Kinzler, K. W.; Velculescu, V. E.; Vogelstein, B.; Bigner, D. D. IDH1 and IDH2 mutations in gliomas N. Engl. J. Med. 2009, 360, 765-773
8. Hartmann, C.; Meyer, J.; Balss, J.; Capper, D.; Mueller, W.; Christians, A.; Felsberg, J.; Wolter, M.; Mawrin, C.; Wick, W.; Weller, M.; Herold-Mende, C.; Unterberg, A.; Jeuken, J. W.; Wesseling, P.; Reifenberger, G.; von Deimling, A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas Acta Neuropathol. 2009, 118, 469-474
9. Marcucci, G.; Maharry, K.; Wu, Y.-Z.; Radmacher, M. D.; Mrózek, K.; Margeson, D.; Holland, K. B.; Whitman, S. P.; Becker, H.; Schwind, S.; Metzeler, K. H.; Powell, B. L.; Carter, T. H.; Kolitz, J. E.; Wetzler, M.; Carroll, A. J.; Baer, M. R.; Caligiuri, M. A.; Larson, R. A.; Bloomfield, C. D. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study J. Clin. Oncol. 2010, 28, 2348-2355
10. Figueroa, M. E.; Abdel-Wahab, O.; Lu, C.; Ward, P. S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H. F.; Tallman, M. S.; Sun, Z.; Wolniak, K.; Peeters, J. K.; Liu, W.; Choe, S. E.; Fantin, V. R.; Paietta, E.; Löwenberg, B.; Licht, J. D.; Godley, L. A.; Delwel, R.; Valk, P. J.; Thompson, C. B.; Levine, R. L.; Melnick, A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 2010, 18, 553-567
11. Amary, M. F.; Bacsi, K.; Maggiani, F.; Damato, S.; Halai, D.; Berisha, F.; Pollock, R.; O'Donnell, P.; Grigoriadis, A.; Diss, T.; Eskandarpour, M.; Presneau, N.; Hogendoorn, P. C.; Futreal, A.; Tirabosco, R.; Flanagan, A. M. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours J. Pathol. 2011, 224, 334-343
12. Dang, L.; White, D. W.; Gross, S.; Bennett, B. D.; Bittinger, M. A.; Driggers, E. M.; Fantin, V. R.; Jang, H. G.; Jin, S.; Keenan, M. C.; Marks, K. M.; Prins, R. M.; Ward, P. S.; Yen, K. E.; Liau, L. M.; Rabinowitz, J. D.; Cantley, L. C.; Thompson, C. B.; van der Heiden, M. G.; Su, S. M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 2009, 462, 739-744
13. Ward, P. S.; Patel, J.; Wise, D. R.; Abdel-Wahab, O.; Bennett, B. D.; Coller, H. A.; Cross, J. R.; Fantin, V. R.; Hedvat, C. V.; Perl, A. E.; Rabinowitz, J. D.; Carroll, M.; Su, S. M.; Sharp, K. A.; Levine, R. L.; Thompson, C. B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 2010, 17, 225-234
14. Lu, C.; Ward, P. S.; Kapoor, G. S.; Rohle, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C. R.; Khanin, R.; Figueroa, M. E.; Melnick, A.; Wellen, K. E.; O'Rourke, D. M.; Berger, S. L.; Chan, T. A.; Levine, R. L.; Mellinghoff, I. K.; Thompson, C. B. IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 2012, 483, 474-478
15. Turcan, S.; Rohle, D.; Goenka, A.; Walsh, L. A.; Fang, F.; Yilmaz, E.; Campos, C.; Fabius, A. W.; Lu, C.; Ward, P. S.; Thompson, C. B.; Kaufman, A.; Guryanova, O.; Levine, R.; Heguy, A.; Viale, A.; Morris, L. G.; Huse, J. T.; Mellinghoff, I. K.; Chan, T. A. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 2012, 483, 479-483
16. Prensner, J. R.; Chinnaiyan, A. M. Metabolism unhinged: IDH mutations in cancer Nat. Med. 2011, 17, 291-293
17. Dang, L.; Jin, S.; Su, S. M. IDH mutations in glioma and acute myeloid leukemia Trends Mol. Med. 2010, 16, 387-397
18. Garber, K. Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia J. Natl. Cancer Inst. 2010, 102, 926-928
19. Popovici-Muller, J.; Saunders, J. O.; Salituro, F. G.; Travins, J. M.; Yan, S.; Zhao, F.; Gross, S.; Dang, L.; Yen, K. E.; Yang, H.; Straley, K. S.; Jin, S.; Kunii, K.; Fantin, V. R.; Zhang, S.; Pan, Q.; Shi, D.; Biller, S. A.; Su, S. M. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo ACS Med. Chem. Lett. 2012, 3, 850-855
20. Rohle, D.; Popovici-Muller, J.; Palaskas, N.; Turcan, S.; Grommes, C.; Campos, C.; Tsoi, J.; Clark, O.; Oldrini, B.; Komisopoulou, E.; Kunii, K.; Pedraza, A.; Schalm, S.; Silverman, L.; Miller, A.; Wang, F.; Yang, H.; Chen, Y.; Kernytsky, A.; Rosenblum, M. K.; Liu, W.; Biller, S. A.; Su, S. M.; Brennan, C. W.; Chan, T. A.; Graeber, T. G.; Yen, K. E.; Mellinghoff, I. K. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells Science 2013, 340, 626-630
21. Zheng, B.; Yao, Y.; Liu, Z.; Deng, L.; Anglin, J. L.; Jiang, H.; Prasad, B. V.; Song, Y. Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase ACS Med. Chem. Lett. 2013, 4, 542-546
22. Deng, L.; Sundriyal, S.; Rubio, V.; Shi, Z.; Song, Y. Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy- d -xylulose-5-phosphate reductoisomerase J. Med. Chem. 2009, 52, 6539-6542
23. Deng, L.; Endo, K.; Kato, M.; Cheng, G.; Yajima, S.; Song, Y. Structures of 1-Deoxy- d -Xylulose-5-Phosphate Reductoisomerase/Lipophilic Phosphonate Complexes ACS Med. Chem. Lett. 2011, 2, 165-170
24. Xue, J.; Diao, J.; Cai, G.; Deng, L.; Zheng, B.; Yao, Y.; Song, Y. Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase ACS Med. Chem. Lett. 2013, 4, 278-282
25. Yang, B.; Zhong, C.; Peng, Y.; Lai, Z.; Ding, J. Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H Cell Res. 2010, 20, 1188-1200
26. Jin, G.; Pirozzi, C. J.; Chen, L. H.; Lopez, G. Y.; Duncan, C. G.; Feng, J.; Spasojevic, I.; Bigner, D. D.; He, Y.; Yan, H. Mutant IDH1 is required for IDH1 mutated tumor cell growth Oncotarget 2012, 3, 774-782
27. Hellinger, E.; Veszelka, S.; Toth, A. E.; Walter, F.; Kittel, A.; Bakk, M. L.; Tihanyi, K.; Hada, V.; Nakagawa, S.; Duy, T. D.; Niwa, M.; Deli, M. A.; Vastag, M. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models Eur. J. Pharm. Biopharm. 2012, 82, 340-351
28. Lv, H.; Zhang, X.; Sharma, J.; Reddy, M. V. R.; Reddy, E. P.; Gallo, J. M. Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy AAPS J. 2013, 15, 250-257
29. Luchman, H. A.; Stechishin, O. D.; Dang, N. H.; Blough, M. D.; Chesnelong, C.; Kelly, J. J.; Nguyen, S. A.; Chan, J. A.; Weljie, A. M.; Cairncross, J. G.; Weiss, S. An in vivo patient-derived model of endogenous IDH1-mutant glioma Neuro-Oncology 2012, 14, 184-191
30. Shu, Q.; Wong, K. K.; Su, J. M.; Adesina, A. M.; Yu, L. T.; Tsang, Y. T.; Antalffy, B. C.; Baxter, P.; Perlaky, L.; Yang, J.; Dauser, R. C.; Chintagumpala, M.; Blaney, S. M.; Lau, C. C.; Li, X. N. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma Stem Cells 2008, 26, 1414-1424
31. Liu, Z.; Zhao, X.; Mao, H.; Baxter, P. A.; Huang, Y.; Yu, L.; Wadhwa, L.; Su, J. M.; Adesina, A.; Perlaky, L.; Hurwitz, M.; Idamakanti, N.; Police, S. R.; Hallenbeck, P. L.; Hurwitz, R. L.; Lau, C. C.; Chintagumpala, M.; Blaney, S. M.; Li, X. N. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma Neuro-Oncology 2013, 15, 1173-1185
32. Wan, F.; Zhang, S.; Xie, R.; Gao, B.; Campos, B.; Herold-Mende, C.; Lei, T. The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research Brain Pathol. 2010, 20, 877-889
33. Laks, D. R.; Masterman-Smith, M.; Visnyei, K.; Angenieux, B.; Orozco, N. M.; Foran, I.; Yong, W. H.; Vinters, H. V.; Liau, L. M.; Lazareff, J. A.; Mischel, P. S.; Cloughesy, T. F.; Horvath, S.; Kornblum, H. I. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma Stem Cells 2009, 27, 980-987
34. Chaichana, K.; Zamora-Berridi, G.; Camara-Quintana, J.; Quinones-Hinojosa, A. Neurosphere assays: Growth factors and hormone differences in tumor and nontumor studies Stem Cells 2006, 24, 2851-2857
35. Yu, L.; Baxter, P. A.; Voicu, H.; Gurusiddappa, S.; Zhao, Y.; Adesina, A.; Man, T. K.; Shu, Q.; Zhang, Y. J.; Zhao, X. M.; Su, J. M.; Perlaky, L.; Dauser, R.; Chintagumpala, M.; Lau, C. C.; Blaney, S. M.; Rao, P. H.; Leung, H. C.; Li, X. N. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo Neuro-Oncology 2010, 12, 580-594
36. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M. A.; Dick, J. E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 1994, 367, 645-648
37. Al Hajj, M.; Becker, M. W.; Wicha, M.; Weissman, I.; Clarke, M. F. Therapeutic implications of cancer stem cells Curr. Opin. Genet. Dev. 2004, 14, 43-47
38. Zhou, H.; Shen, T.; Luo, Y.; Liu, L.; Chen, W.; Xu, B.; Han, X.; Pang, J.; Rivera, C. A.; Huang, S. The antitumor activity of the fungicide ciclopirox Int. J. Cancer 2010, 127, 2467-2477
39. Eberhard, Y.; McDermott, S. P.; Wang, X.; Gronda, M.; Venugopal, A.; Wood, T. E.; Hurren, R.; Datti, A.; Batey, R. A.; Wrana, J.; Antholine, W. E.; Dick, J. E.; Schimmer, A. D. Blood 2009, 114, 3064-3073
40. Deodhar, K. D.; Kekare, M. B.; Pednekar, S. R. A Facile Synthesis of 2-Pyridones by Nucleophilic Reaction on Pyran2-thiones Synthesis 1985, 328-331
41. Batt, D. G.; Maynard, G. D.; Petraitis, J. J.; Shaw, J. E.; Galbraith, W.; Harris, R. R. 2-Substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity J. Med. Chem. 1990, 33, 360-370